Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22927815 | 1.00 | DPP4 (0.38) | DPP4F2AKT2ROCK1ADRA2A | |
| SCHEMBL12851473 | 0.80 | CYP1A2 (0.42) | ROCK1CYP1A2LMNAKDM4E | |
| SCHEMBL11542035 | 0.80 | SLC6A2 (0.55) | P2RX7CYP1A2CYP2A6LMNA | |
| Hydrochloric Acid SCHEMBL4527621 | 0.79 | CYP1A2 (0.41) | ROCK1CYP1A2LMNAKDM4E | |
| SCHEMBL14511065 | 0.77 | SMN1; SMN2 (0.58) | P2RX7LMNAKDM4E | |
| SCHEMBL3386704 | 0.77 | AKT2 (0.41) | DPP4F2AKT2ADRA2AADRA2C | |
| SCHEMBL3382818 | 0.77 | CYP3A4 (0.42) | DPP4F2AKT2 | |
| SCHEMBL14808807 | 0.77 | DPP4 (0.38) | DPP4F2AKT2SCN4A | |
| SCHEMBL3382791 | 0.77 | KDM1A (0.40) | DPP4F2AKT2 | |
| SCHEMBL11478580 | 0.76 | DPP4 (0.61) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289728-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289728-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | DPP4 2555/4885F2 4729/4885AKT2 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.